Emily Behling, MD
Clinical FellowDownloadHi-Res Photo
About
Copy Link
Titles
Clinical Fellow
Biography
Emily Behling, MD is a clinical fellow and Chief Resident in the Albert J. Solnit Integrated Child, Adolescent and Adult Psychiatry Program. Dr. Behling received her B.S. in Biology from the University of Connecticut and her M.D. from the University of Connecticut School of Medicine. Her research interests involve using advanced meta-analytic techniques and clinical trials to improve the understanding and pharmacological treatments of mental health conditions affecting children and adults including Tourette syndrome, attention-deficit/hyperactivity disorder and anxiety disorders.
Last Updated on January 04, 2026.
Education & Training
- MD
- University of Connecticut School of Medicine
- BS
- University of Connecticut, Biology
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Emily Behling's published research.
Publications Timeline
A big-picture view of Emily Behling's research output by year.
Michael Bloch, MD, MS
Luis Farhat, MD, PhD
Angeli Landeros-Weisenberger, MD
Adam Lombroso
Madeeha Nasir
Victor J. Avila-Quintero, MD
8Publications
125Citations
Publications
2026
Anxiety disorders
Behling E, Taylor JH, Lebowitz ER, Bloch MH, Silverman WK. Anxiety disorders. In: van Schalkwyk GI, Volkmar FR, Martin A, Stevens HE, Bloch MH. Lewis’s Child and Adolescent Psychiatry: A Comprehensive Textbook, 6th ed. Wolters Kluwer; 2026.Chapters
2025
Racial, Ethnic and Sex Representation in Tourette's Syndrome Clinical Trials: A Meta‐Analysis
Behling E, Farhat L, Landeros‐Weisenberger A, Bloch M. Racial, Ethnic and Sex Representation in Tourette's Syndrome Clinical Trials: A Meta‐Analysis. Movement Disorders Clinical Practice 2025 PMID: 41392858, DOI: 10.1002/mdc3.70457.Peer-Reviewed Original ResearchConceptsRandomized Controlled TrialsParticipation-to-prevalence ratioRandom-effects meta-analysisMeta-analysisProportion of trial participantsEvidence-based treatmentsClinical trialsReporting of raceHealth disparitiesProportion of individualsTS medicationEthnicity dataWeb of Science Core CollectionUS populationTrial participantsMeta-RegressionMinority participantsSex subgroupsScience Core CollectionPrimary outcomeMinority individualsTourette syndromeDisparitiesParticipantsTemporal trends
2024
Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette’s Disorder Medications
Macul Ferreira de Barros P, Farhat L, Behling E, Nasir M, Landeros-Weisenberger A, Bloch M. Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette’s Disorder Medications. Journal Of The American Academy Of Child And Adolescent Psychiatry 2024, 64: 577-592. PMID: 39505141, DOI: 10.1016/j.jaac.2024.10.011.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDrug-placebo differencesMagnitude of placebo responseTourette's disorderPaper self-identifiesPlacebo responseRandomized Controlled TrialsDrug responseChronic tic disorderAssociated with greater improvementStandardized mean changePlacebo armPlacebo-controlled randomized controlled trialsPharmacological interventionsMeta-analysisAssociated with larger improvementsStudy-level factorsClinical trialsPharmacological randomized controlled trialsDrug placeboPlacebo-controlled clinical trialPsychiatric conditionsControlled TrialsTic disordersTourette syndromeTourettePharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis
Farhat L, Behling E, Landeros-Weisenberger A, de Barros P, Polanczyk G, Cortese S, Bloch M. Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 373-382. PMID: 39320340, PMCID: PMC11807863, DOI: 10.1089/cap.2024.0049.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsADHD symptomsAttention-deficit/hyperactivity disorderTic severityTourette's disorderAttention-deficit/hyperactivityRandomized Controlled TrialsA2 agonistPharmacological interventionsADHD symptom severityIncreased tic severityPersistent tic disordersNetwork Meta-AnalysisStandardized mean differencePairs of medicationsEfficacy of pharmacological interventionsWorsen ticsRandom-effects network meta-analysisSymptom severityTic disordersADHDMeta-analysisNetwork meta-analysis frameworkCertainty of evidenceDisordersNetwork meta-analyses
2022
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAntipsychotic drugsTourette syndromeComorbid attention-deficit hyperactivity disorderSecond-generation antipsychotic drugsModerate certainty of evidenceAttention-deficit hyperactivity disorderCertainty of evidenceNetwork Meta-AnalysisPharmacological interventionsSeverity of tic symptomsObsessive-compulsive disorderIndividual medicationsRandomised controlled trialsFirst-generationDiscontinuation due to adverse eventsSecond-generationAntipsychotic medicationControlled TrialsModerate certaintyHyperactivity disorderMeta-analysisTic symptomsChoice of medicationMedication categoriesTouretteMeta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders
Behling E, Farhat LC, Landeros‐Weisenberger A, Bloch MH. Meta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders. Movement Disorders 2022, 37: 684-693. PMID: 35191552, DOI: 10.1002/mds.28957.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVesicular monoamine transporter type 2Treatment of tic disordersChronic tic disorderRandomized Controlled TrialsVMAT2 inhibitorsTic disordersMeta-analysisTourette syndromeOdds ratioVesicular monoamine transporter type 2 inhibitorsYale Global Tic Severity ScaleMean differenceRate of discontinuationType 2 inhibitorsTic Severity ScaleDouble-blind RCTShort-term treatmentRandom-effects meta-analysisTic severityTic symptomsEffective therapyEffect size indexControlled TrialsType 2Severity ScaleThe effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis
Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, Polanczyk GV, Bloch MH. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular Psychiatry 2022, 27: 1562-1572. PMID: 35027679, DOI: 10.1038/s41380-021-01391-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAttention-deficit/hyperactivity disorderFixed-dose trialDoses of stimulantsFlexible-dose trialDiscontinuation due to adverse eventsAdverse eventsAttention-deficit/hyperactivityBenefits of stimulationAttention-deficit/hyperactivity disorder symptomsTreat attention-deficit/hyperactivity disorderHigh doses of stimulantsPresence of ADHD symptomsFlexible-dose designDaily doseDosing strategiesStimulation doseRandom-effects dose-response meta-analysesClinical practiceTreatment discontinuation due to adverse eventsHigh dosesIncremental benefitDose-limiting adverse eventsDose-response meta-analysisMeta-analysesTreatment of children/adolescents
2021
Don’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too
Behling E, Bloch MH. Don’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too. Biological Psychiatry 2021, 90: 212-213. PMID: 34325804, DOI: 10.1016/j.biopsych.2021.06.010.Peer-Reviewed Original ResearchAltmetricMeSH Keywords
News
Copy Link